UPDATE: Ventus Therapeutics Announces Positive Phase 1 Trial Results for Investigational Drug, VENT-03, for Lupus

Ventus Therapeutica announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to conduct a phase 2 studying for people with systemic lupus erythematosus (SLE) by 2025.

The first drug of its kind to advance in clinical development, VENT-03 is an oral therapy designed to target and inhibit cGAS, a cell receptor linked to lupus, and a wide range of other drugs. autoimmune diseases. The phase 1 study examined pharmacokinetics, target engagement, safety and tolerability in 72 healthy adult volunteers. The results showed that VENT-03 was safe and well tolerated at all dose levels tested, with all treatment-related side effects being mild and easily controlled. VENT-03 demonstrated a favorable pharmacokinetic profile, supporting once-daily dosing. Furthermore, VENT-03 achieved plasma concentrations needed for full target inhibition and showed strong pharmacodynamic (what a drug does to the body) effects.

Stay tuned to the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about medications used to treat lupus.

Read the announcement